Clinical trial
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
NCT01678898 · Protalix, Industry · Completed
Key facts
| NCT number | NCT01678898 |
|---|---|
| Title | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients |
| Official title | A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Months to Adult Fabry Patients |
| Lead sponsor | Protalix, Industry |
| Collaborators | Chiesi Farmaceutici S.p.A. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | PRX-102 |
| Enrollment | 18 |
| Start date | Oct 1, 2012 |
| Primary completion | Mar 6, 2016 |
| Completion | Mar 6, 2016 |
| First posted | Sep 5, 2012 |
| Last update posted | Sep 13, 2023 |
| Countries | Australia, Paraguay, Serbia, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: